Dr. Alane Izu is a Biostatistician at the Vaccine and Infectious Disease Analytics (VIDA) Research Unit at the University of the Witwatersrand. Dr Izu’s research focuses particularly on vaccine impact, infectious disease epidemiology, immunogenicity and colonisation studies in South Africa. Among her notable contributions are longitudinal analyses of pneumococcal conjugate vaccine (PCV) impact in children, and work on serological thresholds associated with risk reduction of invasive Group B Streptococcus (GBS) disease.

In her current role at Wits-VIDA, Dr. Izu supports analytical methods for both observational studies and clinical trials within the unit. She contributes to the design and analysis of vaccine effectiveness and immunogenicity studies focused on pneumococcal disease, GBS, and respiratory tract infections in infants and young children. Her recent methodological work includes developing approaches for establishing serological thresholds of risk reduction (SToRR) for Klebsiella pneumoniae and E. Coli and identifying correlates of protection for respiratory syncytial virus (RSV) associated illness and enteric diseases. Her research contributes directly to evidence-based vaccine policy in low- and middle-income countries and supports global health efforts to reduce the burden of childhood infectious diseases.